John Renger, Chief Scientific Officer at Cerevel Therapeutics Holdings, Inc. (CERE), sold 30,000 shares at $32.50 ($1.0M) on 2022-03-09, disclosed to the SEC on 2022-03-11.
Open-market sale of $1.0M CERE by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.50 | 20,000 | $650K | 65.0% |
| 2 | $35.00 | 10,000 | $350K | 35.0% |
| Total | $33.33 avg | 30,000 | $1.0M | 100% |
| Filing → |
| CERE | SELL | 2022-10-06 | $750K | — | Filing → |
| CERE | SELL | 2022-08-12 | $4.5M | — | Filing → |
| CERE | SELL | 2022-08-09 | $1.0M | — | Filing → |